This document is available in two formats: this web page (for browsing content) and
PDF (comparable to original document
formatting). To view the PDF you will need Acrobat Reader, which may be downloaded from the Adobe site. For an official signed copy, please contact the
Antitrust Documents Group.

JUSTICE DEPARTMENT WILL NOT CHALLENGE PROPOSED CHANGES TO
AMERICAN HEART ASSOCIATION PHARMACEUTICAL ROUNDTABLE

WASHINGTON, D.C. -- The Department of Justice said today
that it would not challenge the proposed changes in the
activities of the Pharmaceutical Roundtable (PRT) of the American
Heart Association (AHA).

The Pharmaceutical Roundtable sponsors and funds basic
biomedical research by independent researchers to study the
causes, prevention, and treatment of various cardiovascular
diseases, including stroke.

Based on information provided by the parties, the Department
said the PRT's future activities are not likely to lessen
competition substantially.

"The Department will not challenge a true joint research and
development venture on antitrust grounds unless on balance, the
venture will have anticompetitive effects", said Joel I. Klein,
Assistant Attorney General in charge of the Antitrust Division.
"Joint ventures to perform basic, non-appropriable research, like
the PRT, are not usually on balance anticompetitive."

Under the proposal, the PRT will target specific areas of
interest in the cardiovascular field and fund basic research into
the outcomes and health services related to those areas of
interest. The PRT also proposes to change its members' annual
contributions from the current level of $200,000 ($300,000 for
the Founding Members) to $1,000,000, and the term of its members'
agreements from the current level of five years to three years.
The combined annual contributions will continue to be used to
fund basic research projects selected by vote of the PRT' s
members from a list of projects previously reviewed and approved
by the AHA.

All pharmaceutical manufacturers, foreign and domestic, will
continue to be eligible for membership in the PRT. There are
currently no plans to limit the number of members active in the
PRT, or to close membership.

Research funded by the PRT will not be oriented toward the
improvement or development of commercial products. Any knowledge
obtained from the research will be published and otherwise made
public, not used privately by the AHA or any member of the PRT.

The PRT' s members will neither initiate nor design research
projects for review and approval of the AHA. Research projects
will continue to be performed by independent researchers at their
academic or other nonprofit institutions, and will be monitored
by those institutions, not by the members of the PRT.

The members of the PRT remain free to select and fund
through the PRT additional research projects approved by the AHA.
The members are not in any way limited in conducting or funding
research independent of the PRT.

The PRT' s members will continue to have no rights to
patents or other interests resulting from research funded by or
through the PRT. However, members of the PRT may associate their
firms' names with the additional research projects they fund
through the PRT, and may use a specially designed logo in their
own advertising to publicize their support for, and membership
in, the PRT.

The Department's position was stated in a business review
letter issued by the Antitrust Division. The Department reserves
the right to bring an enforcement action against the PRT if those
activities should prove to have an anticompetitive effect.

Under the Department' s business review procedure, an
organization may submit a proposed action to the Antitrust
Division and receive a statement as to whether the Division will
challenge the action under the antitrust laws.

A file containing the business review request and the
Department' s response may be examined in the Antitrust Documents
Group of the Antitrust Division, Suite 215 Liberty Place, 325 7th
Street, N.W., Department of Justice, Washington, D.C. 20004.
After a 30-day waiting period, the documents supporting the
business review will be added to the file, unless a basis for
their exclusion for reasons of confidentiality has been
stablished pursuant to Paragraph 10(c) of the Business Review
Procedure.